[Key points and interpretation of Chinese expert's consensus on endocrine therapy of breast cancer (2026 edition)]

Based on the 2023 consensus, the Chinese Breast Cancer Endocrine Therapy Consensus Group systematically reviewed the key points of endocrine therapy in the neoadjuvant, adjuvant, and metastatic settings, and updated the 2026 edition consensus. We interpreted the key points of the consensus in this article. In precision testing, the consensus emphasized the standard immunohistochemical test for hormone receptor and human epidermal growth factor receptor 2 (HER2) receptor, defined HER2-low and ultra-low expression, clarified the timing and methods of genetic testing. For different treatment stages of breast cancer, the consensus defined the eligible population for neoadjuvant endocrine therapy, expanded adjuvant cyclin-dependent kinases 4/6 (CDK4/6) inhibitor application in moderate and high-risk patients, optimized treatment strategies for first-line endocrine therapy plus CDK4/6 inhibitors in metastatic breast cancer, and recommended preferred regimens for post-CDK4/6 inhibitor patients. In conclusion, clinicians should follow the consensus recommendations, so as to achieve precise and individualized treatment for patients with hormone receptor-positive breast cancer.